Breakthrough technology points to a new era for liver transplantation

OrganOx is delighted to announce the publication of a multinational clinical trial  ('A randomized trial of normothermic preservation in liver transplantation') in Nature, the international journal of science.

In the first randomized study of its kind, transplanted livers were shown to function better if they had been preserved using the OrganOx metra device. This benefit was most pronounced in the most ‘marginal’ donor livers.   Preservation using the metra device was also associated with increased use of available donor organs.

Funded by the European Commission, 220 livers were transplanted in this randomized controlled study across seven European transplant centres. Conventional organ preservation, in an ice box, (static cold storage (SCS)) was compared with storage using the metra device.

Whereas the traditional method of organ preservation requires cooling and storage in an ice box, normothermic machine perfusion with the OrganOx metra device maintains the liver at normal body temperature prior to transplantation and actively delivers oxygenated blood, medications and nutrients. This greatly reduces the tissue injury associated with transplantation and enables quality assessment by functional testing of the organ.

“We are in the business of saving lives by saving donor organs” said Craig Marshall, CEO of OrganOx Ltd. “By changing the way the donor livers are preserved and evaluated before they are transplanted, we expect to see more donor livers being transplanted. Our company is at the forefront of this exciting new technology, and we are also researching other applications for our platform to help address liver disease – which is predicted to become the largest cause of premature deaths by 2020.”    

To read the study visit https://www.nature.com/articles/s41586-018-0047-9 or to read the article visit https://www.nature.com/articles/d41586-018-04816-8

 

OrganOx_metra_Setup.jpg

Pioneering Clinical Trial Featured by BBC

The OrganOx metra device was recently featured in use for a pioneering clinical trial (VITTAL) by the liver transplant team at the Queen Elizabeth II Hospital, Birmingham, UK. This pioneering study team is placing livers declined for transplant by all UK liver transplant centres on the OrganOx metra device, assessing their quality, and if deemed viable, transplanting them.  Watch the documentary on BBC iPlayer (only available within the UK) HERE

BBC image .jpg

OrganOx signs 5 year distribution agreement with Dismeval for Spanish distribution of the OrganOx metra device

OrganOx, a leader in the field of organ preservation,  has signed a 5 year agreement with Dismeval to distribute the OrganOx metra in Spain.

" We are delighted to have signed up Dismeval s.l  to ensure the OrganOx metra is adopted in Spain. In terms of organ donation rates Spain leads the rest of the world, very much helped by the opt-out policy which has been in place since 1979.  We have been  impressed with Dismeval's track record over many years in driving other innovative surgical products into the Spanish market. With Dismeval as our partner in Spain we look forward to seeing the positive impact of our technology benefiting all involved in liver transplantation. " said Craig Marshall, CEO of OrganOx Limited.

"We recognise  the potential of the OrganOx metra to further improve the  utilisation of deceased donor livers in Spain. We anticipate first sales into leading Spanish liver transplant hospitals centres in Q4 of 2017" said  Salvador Forés, General Manager of Dismeval s.l.

OrganOx signs 5 year agreement with Avidal Group GmbH for distribution in Germany, Austria and Switzerland

OrganOx, a leader in the field of organ preservation,  has signed a 5 year agreement with Avidal Group GmbH to distribute the OrganOx metra in Germany, Austria and Switzerland.

As part of the agreement Avidal is committed to securing marketing approval for the CE marked metra in each of these 3 countries.

“ We are delighted to have signed up the Avidal Group to ensure the OrganOx metra is adopted in these 3 key European countries. We have been  impressed with Avidal’s track record over many years in driving other innovative surgical and interventional products into these markets. With Avidal as our partner in Germany, Austria and Switzerland we look forward to establishing a significant presence in these countries in the coming years” said Craig Marshall, CEO of OrganOx Limited.

“We recognise  the potential of the OrganOx metra to dramatically improve the  utilisation of deceased donor livers, we see a huge opportunity for this product in the countries we serve. The marketing approval process in Germany is particularly complex, but it a process we at Avidal Group  understand very well, and in the case of the OrganOx metra we actually began this process, in good faith, almost 12 months ago. We anticipate first sales into German liver transplant hospitals centres in Q4 of 2017” said Torsten Heilmann, CEO of Avidal Group GmbH.